The online tool was evaluated in a cohort of 501 patients and healthcare providers, showing positive trends in 9 of 11 outcomes assessed. Notably, disease-modifying therapy start, adherence, and long-term mental health were all improved in the intervention group.
Clinician-perceived cognitive deficits of patients with multiple sclerosis were significantly predicted by multiple factors, including cognitive scores, depression, and physical disability, but notably not fatigue.
The 1st annual awards ceremony was held during the CMSC Annual Meeting in National Harbor, Maryland.
Individuals with progressive MS demonstrated stable scores on Expanded Disability Status Scale, with no 12-week confirmed disability progression detected.
The associate professor of neurology at UCSF Weill Institute for Neurosciences discussed the findings of a social media listening study that suggested women with multiple sclerosis used social media platforms to discuss treatment during and around pregnancy. [WATCH TIME: 4 minutes]
The form, which is freely available through the Epic and Cerner EHR platforms, was developed to streamline and standardize patient data collection to allow clinicians more time with patients and more consistent information.
The health research assistant at the Shepherd Center discussed the need to improve access to interventions that improve the overall happiness of individuals with multiple sclerosis. [WATCH TIME: 4 minutes]
A large number of patients with MS were clustered in an area that may have had high exposure levels of aluminum, which the study investigators noted warrants future research.
The professor of neurology at the University of Saskatchewan discussed the need to improve therapeutics aimed at improving neurodegeneration in patients with multiple sclerosis. [WATCH TIME: 3 minutes]
At the end of the open-label extension period, 77.5% of patients reported treatment-emergent adverse events and 27.7% had a treatment-related TEAE.
Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.
Although there were no differences between herpes simplex virus types 1 and 2, patients with MS did show increased levels of EBV capsid antigen and EBNA compared with controls.
Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.
The professor of neurology at the University of Saskatchewan discussed his presentation at the 2022 CMSC Annual Meeting on using ribonucleoprotein A1 antibodies to drive neurodegeneration in multiple sclerosis. [WATCH TIME: 4 minutes]
June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]
The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]
The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]
The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps in how we can expand on tears as a valuable biomarker for neurodegenerative diseases. [WATCH TIME: 4 minutes]
The director of the Division of Movement Disorders at the USC Keck School of Medicine commented on the potential of reflex tears as a critical biomarker of Parkinson disease. [WATCH TIME: 6 minutes]
The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]
Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]
After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.
